| Identification | Back Directory | [Name]
2-(4-Hydroxyphenyl)benzo[b]thiophene-6-ol | [CAS]
63676-22-2 | [Synonyms]
Raloxifene Impurity 4
Raloxifene InterMediate
Estrogen receptor modulator 1
BTC (Estrogen receptor modulator 1)
2-(4-Hydroxyphenyl)benzothiophene-6-ol
2-(4-Hydroxyphenyl)benzo[b]thiophen-6-ol
2-(4-hydroxyphenyl)-1-benzothiophen-6-ol
2-(4-Hydroxyphenyl)benzo[b]thiophene-6-ol
2-(4-hydroxyphenyl)-1-benzothiophene-6-ol
Benzo[b]thiophene-6-ol, 2-(4-hydroxyphenyl)-
6-Hydroxy-2-(4-Hydroxyphenyl)Benzo[B]Thiophene | [Molecular Formula]
C14H10O2S | [MDL Number]
MFCD16619490 | [MOL File]
63676-22-2.mol | [Molecular Weight]
242.293 |
| Chemical Properties | Back Directory | [Melting point ]
295 °C(dec.) | [Boiling point ]
477.0±30.0 °C(Predicted) | [density ]
1.383 | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
9.32±0.15(Predicted) | [color ]
Pale Grey |
| Hazard Information | Back Directory | [Uses]
2-(4-Hydroxyphenyl)benzo[b]thiophen-6-ol is used in the synthesis of Raloxifene (R100000) an estrogen receptor modulator. | [in vivo]
Estrogen receptor modulator 1 (1.5 mg/animal; p.o. ; daily for 2 weeks) results in regression of T47D:A18/PKCα tumors[2]. | Animal Model: | 4-6 week old athymic mice (Harlan-Sprague-Dawley)[2] | | Dosage: | 1.5 mg/animal | | Administration: | p.o. ; daily for 2 weeks | | Result: | Significantly reduced tumor volume.
|
|
|
|